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Abstract 
First generation immune checkpoint inhibitors including anti-CTLA-4 and anti-PD-1 
antibodies have led to major clinical progress, yet resistance frequently leads to 
treatment failure. Thus, new targets acting on T cells are needed. CD33-related Siglecs 
are pattern recognition immune receptors binding to a range of sialoglycan ligands, 
which appear to function as self-associated molecular patterns (SAMPs) that suppress 
autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and 
these receptors were not yet considered as interesting targets on T cells for cancer 
immunotherapy. Here, we show an upregulation of Siglecs including Siglec-9 on tumor-
infiltrating T cells from non-small cell lung cancer (NSCLC), colorectal and ovarian 
cancer patients. Siglec-9 expressing T cells co-expressed several inhibitory receptors 
including PD-1. Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo 
resulted in increased anti-cancer immunity. T cell expression of Siglec-9 in NSCLC 
patients correlated with a reduced survival, and Siglec-9 polymorphisms showed 
associations with the risk of developing lung and colorectal cancer. Our data identify the 
sialoglycan-SAMP/Siglec pathway as new potential target to improve T cell activation 
for immunotherapy. 
 
Brief summary 
Siglec-9 was identified as a new inhibitory immune checkpoint on tumor-infiltrating CD8+ 
T cells. Targeting of Siglecs led to an increased anti-tumor activity by T cells. 
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Introduction 
The landscape of oncological practice has significantly changed with the introduction of 
immune checkpoint inhibitors that target inhibitory receptors on the surface of CD8+ T 
cells (1). In particular, blocking of the inhibitory receptor programmed death (PD)-1 or its 
ligand PD-L1 has been shown to induce durable responses across many different 
cancer types including non-small cell lung cancer (NSCLC), melanoma, squamous 
carcinoma of the head and neck, kidney cancer or ovarian cancer (1, 2). However, most 
patients have primary resistance to therapeutic PD-(L)1 blockade or develop secondary 
resistance (2). Thus, identification of additional pathways mediating suppression of 
tumor-specific T cells are clearly needed to increase therapeutic efficacy of PD-(L)1 
targeting strategies. 
 
Pattern recognition receptors (PRRs) such as Toll-like receptors or nucleotide-binding 
oligomerization domain (NOD)-like receptors detect pathogens or danger signals and 
engagement of these PRRs by pathogen-associated molecular patterns (PAMPs) or 
damage-associated molecular patterns (DAMPs) activate the respective immune cells 
(3-6). Receptors that bind to PAMPs and DAMPs have also been implicated in cancer 
progression and anti-cancer immunity (6, 7). In addition to these well-described 
pathways, sialoglycans have been shown to serve as a ‘self-associated molecular 
patterns’ (SAMPs) by binding to CD33-related sialic acid-binding immunoglobulin-like 
lectins (CD33rSiglecs) (8, 9), a family of receptors on immune cells containing 
intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM) (10-13). Unlike the 
conserved Siglecs (Siglec-1, Siglec-2, Siglec-4 and Siglec-15), CD33rSiglecs including 
Siglec-3 (CD33), -5, -6, -7, -8, -9, -10, -11, -14 and -16 have evolved rapidly due to 
multiple selection forces, including evolutionary pressure by pathogens that can mimic 
sialoglycan-SAMPs (Sia-SAMPs) and bind to inhibitory CD33rSiglecs to escape innate 
immune control (14-18). The different Siglecs have different binding preferences for 
sialoglycan ligands (9). While Siglec-8 has a more defined spectrum of ligands that 
include 6’-sulfo-sialyl Lewis x (19, 20), Siglec-9 has much broader binding spectrum of 
sialylated ligands (9, 21). Siglec-9 is therefore a typical PRR for Sia-SAMPs. 
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Recent evidence suggests that the upregulation of Sia-SAMPs can facilitate evasion of 
immune control during cancer progression by engaging inhibitory CD33rSiglecs such as 
Siglec-7 and Siglec-9 (21-26). Engagement of Siglec-7 and Siglec-9 inhibits NK cell-
mediated tumor cell killing in vitro (22, 23). Siglec-9 and its murine functional paralog 
Siglec-E have also been implicated in myeloid cell-mediated cancer progression (21, 
24). Binding of the cancer-associated sialylated glycoform of MUC1 to Siglec-9 on 
macrophages can induce a tumor-associated macrophage (TAM) phenotype that can 
promote cancer progression and immune evasion (25). 
 
In chronic infections and cancer, expression of checkpoint molecules including PD-1, 
CTLA-4, TIM-3 and LAG-3 is observed on T cells and is associated with a state of T cell 
dysfunction termed as T cell exhaustion (27). Chronic infections such as HIV have also 
been shown to upregulate inhibitory CD33rSiglecs on peripheral CD4+ T cells, which 
suggests that inhibitory Siglec receptors might be involved in T cell immunoregulation 
(28). In contrast, previous analyses have found very low expression of CD33rSiglecs on 
peripheral T cells of healthy humans (29) and mice (30). We therefore sought to 
characterize the Siglec expression on tumor-infiltrating T cells and to test their functional 
role as new potential immune-checkpoints that are regulated by glycans within the 
tumor microenvironment. 
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Results 
Siglec-9 is upregulated on tumor-infiltrating T cells 
We analyzed the expression of inhibitory CD33rSiglecs on immune cells in primary 
NSCLC samples (Supplemental Figure 1A). As previously described, CD33rSiglecs 
including Siglec-7 and Siglec-9 were expressed on NK cells and Siglec-9 was also 
expressed on myeloid cells (Supplemental Figure 1B). Several inhibitory CD33rSiglecs 
including Siglec-3 (CD33), Siglec-5, Siglec-7, Siglec-10 and Siglec-9 were expressed on 
a significant proportion of tumor-infiltrating lymphocytes (TILs) including CD4+ and CD8+ 
T cells (Figures 1A-1G and Supplemental Figures 1C-1F). Siglec-9 was the most 
prominently and consistently expressed CD33rSiglec on TILs across patients (Figure 
1G). Lower levels of Siglec-9 were observed on peripheral blood T cells from healthy 
donors (Figures 1A-1C) or in spleens from patients undergoing splenectomy for non-
malignant disease (Supplemental Figure 1G). There were a few healthy donors that had 
a larger population of Siglec-9 expressing CD8+ T cells (Figure 1C). In order to further 
understand the heterogeneity of Siglec-9 expression, we further stained Siglec-9 on an 
additional and better characterized population of 49 healthy donors (Supplemental 
Figure 1H). The distribution of Siglec-9 on CD8+ T cells was similar in both cohorts and 
no correlation with the age could be seen (Supplemental Figure 1I). No significant 
difference was seen between genders (9% in men, 7.2% in women Sig9+ CD8+ T cells 
of total CD8+ T cells). We found an inverse correlation of Sig9+ CD8+ with naïve CCR7+ 
CD45RA+ T cells (Supplemental Figure 1J). Immunostaining of intratumoral leukocytes 
showed that Siglec-9 was typically expressed on small lymphocytes and macrophages 
(Figure 1E). Double staining showed that Siglec-9 positive TILs in NSCLC samples also 
expressed CD3 (Figure 1F). We also found an upregulation of Siglec-9 on colorectal 
cancer (CRC) and epithelial ovarian cancer (EOC) TILs or pleural effusions 
(Supplemental Figure 1K). 
There was a significant increase of Sia-SAMPs (Siglec-7 and Siglec-9 ligands) in 
lung carcinomas compared to healthy lung tissue, as well as in acute and chronic 
inflammatory diseases as assessed with Siglec-Fc proteins (Figure 1H and 1I). Ligands 
were strongly present on cytokeratin-positive cells suggesting they are in a trans-
position and a trend for an increase of ligands in higher stage was observed 
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(Supplemental Figure 1L). As Siglec-9 was the most prominent and consistent inhibitory 
CD33rSiglecs upregulated on TILs across different patients, we focused our further 
analysis on Siglec-9. 
 
Characterization of Siglec-9 expressing intratumoral CD8+ T cells. 
We aimed to further characterize the Sig9+ CD8+ TILs in samples from NSCLC patients 
by multicolor flow cytometry. Sig9+ CD8+ TILs co-expressed several other inhibitory 
receptors, including PD-1 in particular and also TIM-3 and LAG-3 (Figures 2A-2B and 
Supplemental Figure 2A-2D). Most Sig9+ CD8+ TILs were found within the population 
with the highest PD-1 expression (PD-1hi, Supplemental Figure 2A). However, not all 
the PD-1hi CD8+ T cells expressed Siglec-9 (Supplemental Figure 2B), suggesting that 
Sig9+ CD8+ TILs are a subpopulation of tumor-specific PD-1hi TILs. Sig9+ CD8+ T cells 
also expressed high levels of the transcription factor Eomesodermin (Eomeshi), and low 
levels of T-bet (Tbetlo, Supplemental Figure 2E). In general, Sig9+ CD8+ TILs had more 
inhibitory receptors upregulated and co-expressed than Sig9- CD8+ TILs from NSCLC 
patients (Figure 2E). Several costimulatory receptors were also enriched on Sig9+ CD8+ 
TILs as compared to Sig9- CD8+ TILs (Supplemental Figures 2F-2J). RNA sequencing 
revealed that several genes were differentially regulated between Sig9+ CD8+ TILs and 
Sig9- CD8+ TILs (Supplemental Figure 2K). The three main genes upregulated in Sig9+ 
CD8+ TILs were SPP1 (osteopontin), Ki67 and KLF4 (Figure 2F). We also looked for the 
expression of genes involved in the generation of Sia-SAMPs. Expression of the rate-
limiting enzyme for sialic acid biosynthesis, UDP-N-acetylglucosamine-2-epimerase 
(GNE), was higher in Sig9+ CD8+ TILs than in Sig9- CD8+ TILs (Supplemental Figure 
2L). Consequently, an upregulation of sialoglycans as shown by increased staining with 
SNA (Supplemental Figure 2M) and an upregulation of cis-ligands on TILs as shown by 
increased staining with Siglec-9-Fc protein (Supplemental Figure 2N). Protein levels of 
osteopontin (SPP1; Supplemental Figure 2O and 2P) and Ki-67 (Supplemental Figure 
2Q) were also significantly higher in Sig9+ CD8+ TILs than in Sig9- CD8+ TILs.  
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Sig9+ TILs are a distinct subset within the CD8+ T cell population. 
We further tested if Siglecs are upregulated by activation of T cells. While Siglec-5 
expression increased significantly on polyclonally activated CD8+ T cells from healthy 
donors, Siglec-9 was only slightly upregulated and Siglec-7 expression was unchanged 
(Supplemental Figure 4A). Antigen-specific stimulation of T cell clones with reactivity 
against peptides from influenza antigens, CMV antigens and melanA led to a slight 
upregulation of Siglec-9 (Supplemental Figure 4B). Sig9+ CD8+ TILs from NSCLC 
samples activated with anti-CD3/anti-CD28 antibodies expressed significantly higher 
surface levels of CD25 (Figure 3A), CD69 (Figure 3B) and the newly identified activation 
marker Siglec-5 (Supplemental Figure 4C) compared with similarly activated Sig9- CD8+ 
TILs. Similar results were seen for polyclonally activated peripheral Sig9+ CD8+ cells 
from healthy donors (Supplemental Figures 4D-4G). CD8+ T cells from NSCLC samples 
were clearly dysfunctional or exhausted as demonstrated by reduced production of 
cytokines such as IFNγ and TNFα compared with CD8+ T cells from healthy donor 
PBMCs (Figures 3C and 3D). However, re-stimulation of TILs from NSCLC patients with 
anti-CD3/anti-CD28 antibodies showed that Sig9+ CD8+ TILs were much easier to re-
stimulate and secrete at higher levels of multiple cytokines including INF-γ than Sig9- 
CD8+ TILs (Figures 3C and 3D, Supplemental Figures 5A-5N). In addition, Sig9+ CD8+ 
cells expressed a distinct pattern of chemokine receptors including CXCR3, CXCR5, 
CCR4, CCR6 and CX3CR1 (Supplemental Figures 5O-5T). A recent study also found a 
subpopulation of PD-1hi CD8+ TILs with a distinct, higher functionality (31); this 
subpopulation was associated with an increased expression of CD5 and a lower 
expression of CD38 and CD101 (31). We therefore stained for these markers and found 
an enrichment of CD5 and Ki67 expression (Figures 3E and 3F) on Sig9+ cells in the 
PD1hi gate as well as a reduced presence of CD38+ and CD101+ (Figure 3G, 
Supplemental Figure 6). Our data provide evidence that intratumoral Sig9+ CD8+ cells 
are a distinct subpopulation of tumor-specific CD8+ TILs. 
 
Sia-SAMP-Siglec-9 interaction is a target to improve T cell activation. 
Next, we wanted to explore the functional implication of Siglec expression on T cells. 
We used the high affinity CD33rSiglec ligand LGALS3BP that is upregulated in NSCLC 
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(24). LGALS3BP inhibited CD8+ T cell activation in a sialic acid-dependent fashion 
(Figure 4A, Supplemental Figures 7A and 7B). We further generated cell lines that 
expressed lower surface levels of Sia-SAMPs by knocking out GNE. GNE-deficient 
A549 lung adenocarcinoma cells showed lower binding to Siglec-9 compared with WT 
A549 cells (Figure 4B). Feeding GNE-KO A549 cells with N-acetylneuraminic acid 
(Neu5Ac) to metabolically bypass the mutation led to a recovery of ligands on the cell 
surface and binding to Siglec-9 (Figure 4B). CD8+ T cell-mediated tumor cell killing was 
tested by co-incubation of T cells from healthy donors and different A549 tumor cell 
variants in the presence of a CD3/EpCAM T cell bispecific (TCB) antibody 
(catumaxomab). T cell-mediated killing of GNE-KO A549 cells and desialylated A549 
cells was higher compared with WT A549 cells and GNE-KO A549 cells fed with 
Neu5Ac (Figure 4C). Similar results were obtained with catumaxomab when using HT29 
tumor cells (Supplemental Figure 7C and Figure 4D) and TILs obtained from primary 
NSCLC samples together with A549 and HT29 cells (Figures 4E and 4F). Experiments 
with the anti-CD3/CD19 TCB antibody blinatumomab and CD19+ Ramos cells (Figure 
4G) or primary CLL samples (Figure 4H) showed similar results. Sig9+ CD8+ T cells 
from NSCLC TILs were significantly more reactive towards GNE-KO A549 cells than 
Sig9- TILs, with the difference being sialic acid-dependent (Figure 4I). Similarly, Sig9+ 
CD8+ T cells induced more apoptosis in HT-29 and Ramos cells respectively than Sig9- 
CD8+ T cells (Supplemental Figures 7E and 7F). 
To test the effect of Siglec-9 blockade on T cell activation in vitro, we used a 
Siglec-9 antibody and the previously described Staphylococcal enterotoxin B (SEB) test 
(32). Two full IgG Siglec-9 antibodies (191240 and E10-286) inhibited T cell activation 
and therefore were agonistic (Supplemental Figures 7G and 7H). Moreover, Siglec-9 
antibodies led to a dose-dependent inhibition of T cell activation tested by upregulation 
of the activation markers CD25 (Figure 4J) and CD69 (Supplemental Figure 7I). 
Addition of the Siglec-9 antibody (clone 191240) inhibited IL-2 production and CD69 
expression on the surface of TILs upon SEB stimulation of primary NSCLC samples 
(Figures 4K and 4L). We hypothesized that bivalent binding and subsequent 
dimerization of Siglec-9 might be responsible for the agonistic effect on Siglec-9 by the 
clone 191240. Indeed, monovalent CRD-blocking Fab fragments from clone 191240 
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(carbohydrate recognition domain (CRD) blocking clone, Supplemental Figure 7J) 
significantly increased IL-2 (Figure 4K) but not CD69 (Figure 4L) production upon SEB 
stimulation. These findings demonstrate that T cell activation in NSCLC tumors can be 
increased by targeting Sia-SAMPs-Siglec-9 interactions. 
 
Siglec-E is expressed on TILs in mice. 
We further investigated if the murine functionally-equivalent paralog (Siglec-E) was 
upregulated on TILs in mouse models. We found a significant upregulation of Siglec-E 
on murine CD8+ TILs when compared with splenocytes from control mice and tumor-
bearing mice in the MC38 subcutaneous tumor model (Figure 5A) and other models 
(LLC, B16 and EMT6 subcutaneous tumor models; Supplemental Figure 8A). While 
other inhibitory CD33rSiglecs including Siglec-F and Siglec-G were also upregulated on 
the surface of murine TILs, Siglec-E was the most prominently upregulated inhibitory 
Siglec tested (Supplemental Figure 8B). We further analyzed the phenotype of SigE+ 
CD8+ murine TILs. The proliferation marker Ki67, the activation markers granzyme B, 
CD69, and the activating receptor CD27 (Figure 5B, and Supplemental Figures 8C-8E) 
were all significantly increased on murine SigE+ CD8+ TILs compared with SigE- CD8+ 
TILs, similar to what is seen in human TIL samples. The expression and number of 
murine inhibitory receptors, including PD-1, was also higher on SigE+ CD8+ TILs than 
SigE- CD8+ (Figures 5C-5E and Supplemental Figures 8F and 8G). SigE+ CD8+ TILs 
were predominantly terminally differentiated Eomeshi, Tbetlo and CD127+ T cells 
(Supplemental Figures 8H). Sorted murine SigE+ CD8+ TILs again showed a stronger 
re-activation than SigE- CD8+ TILs, as shown by upregulation of the activation markers 
CD25 and CD69 (Figure 5G). Taken together, these findings suggest that SigE+ CD8+ 
TILs in mice are phenotypically similar to Sig9+ CD8+ TILs in humans.  
 
Sia-SAMPs mediate immune escape in vivo. 
To further investigate the role of Sia-SAMPs in immune evasion, we generated GNE-
deficient MC38 cells and compared their subcutaneous growth with that of WT MC38 
tumor cells. GNE-KO MC38 tumors showed a clear delay in tumor growth compared to 
WT MC38 tumors injected subcutaneously in C57Bl6 mice (Figure 5H). Similar 
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observations were made for GNE-KO and WT EMT6 tumors injected subcutaneously 
into BALB/c mice (Figure 5I). The GNE-KO cell lines showed no growth difference or 
survival in vitro (Supplemental Figure 8I). The frequencies of CD3+, CD8+, and CD4+ T 
cells in leukocyte infiltrates were significantly higher in GNE-KO MC38 tumors 
compared with WT MC38 tumors (Figures 5J and 5K, Supplemental Figure 8J), 
whereas there was no difference in the infiltration of regulatory T cells (Supplemental 
Figure 8J). GNE-KO tumor infiltrates also contained more classical dendritic cells 
(CD11c+ MHCII+ cells within CD45+ cells) than WT MC38 tumors whereas other myeloid 
cell types did not differ significantly (Supplemental Figure 8J). In order to analyze the 
role of the adaptive immunity, we repeated the experiment in mice deficient for the 
adaptive immune system (NOD-SCID-Gamma, NSG mice). Both MC38 and EMT6 
GNE-KO cell lines showed no growth difference when compared to wildtype (WT) cell 
lines in NSG mice (Supplemental Figure 8K). From these findings, we concluded the 
sialylation directly affects tumor growth and also the anti-tumor immune response by 
enhancing the adaptive immune response to cancer. 
 
Expression of Siglec receptors on T cells directly modulate anti-tumor immunity. 
To further investigate the role of Sia-SAMPs and their interactions with CD33rSiglecs 
we used a human Siglec-9 transgenic mouse (HS9), which allows selective expression 
of Siglec-9 in cells producing Cre recombinase (21). Previous analysis demonstrated 
that human Siglec-9 binds to ligands on murine tumor cells (21). HS9 mice were 
crossed with CD4-Cre mice to express human Siglec-9 in T cells. These mice 
expressed Siglec-9 in both CD4 and CD8 T cells (Supplemental Figure 10A). The 
growth of syngeneic MC38 tumor cells was accelerated in mice expressing Siglec-9 in T 
cells and the tumors grew larger compared to littermate control mice (Figure 6A). This 
finding supports the hypothesis that inhibitory Siglecs on T cells can mediate immune 
evasion. We also used the recently developed Siglec-E16 (SigE16) transgenic mice 
(18). These mice express a chimeric Siglec receptor with the extracellular domain of 
Siglec-E and the transmembrane and intracellular domain of the activating human 
Siglec-16 receptor under Siglec-E promoter (18). No major differences were observed 
between frequency of naïve and memory T cells in different genetic animal models 
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(Supplemental Figure 10B). Siglec-E expression in WT and SigE16 mice was similar 
(Supplemental Figure 10C). Compared with WT littermate control mice, subcutaneous 
syngeneic MC38 tumors grew slower and remained smaller in homozygous SigE16 
mice (Figure 6B). MC38 tumors had an increased induction of anti-tumor antibodies 
(Supplemental Figure 10D). Depletion experiments demonstrated the dependence of 
the effect on both CD4+ and CD8+ T cells and directly showed that the genetic reversal 
of an inhibitory into an activating Siglec receptor can also influence T cell activation 
(Figures 6C and 6D). We also used an adoptive transfer model to study the role of 
Siglec-E on T cells. We transferred OT-I T cells expressing either WT Siglec-E or 
activating SigE16 into WT mice with ovalbumin-expressing MC38-OVA tumors and 
measured the growth of tumors. MC38-OVA tumors in mice transferred with OT-I from 
SigE16 mice had a significantly reduced tumor growth (Figure 6E). In addition, OT-I T 
cells expressing SigE16 had an increased proliferation (Supplemental Figure 10E). In 
addition, also a trend for an increased infiltration was seen in mice adoptively 
transferred with SigE16 expressing OT-I T cells (Supplemental Figure 10F). To 
determine the effect of sialoglycans in trans-position on the growth difference in SigE16 
mice, we used MC38 WT and GNE-KO cells. The previous growth difference could no 
longer be seen in the SigE16 background (Supplemental Figure 10G). This finding 
suggests that the effect seen in SigE16 mice is mediated by interactions of trans-ligands 
with activating SigE16 receptor. 
 
Sig9+ TILs and Siglec-9 polymorphisms are associated with clinical endpoints. 
We further analyzed the correlation of Siglec expression on T cells with clinical 
parameters. Patients with a high frequency of Sig9+ TILs (>30% of CD8+ T cells) had a 
significantly worse overall survival (Figure 6E). The significance was slightly reduced in 
a multivariate analysis taking the age and also the stage into account (p=0.0668 with a 
hazard ratio of 14.6 by a Cox proportional hazard regression analysis). Recently, 
polymorphisms of Siglec-9 were associated with pulmonary diseases (33). We studied if 
the risk to develop lung cancer is associated with the rs2075803 and rs2258983 
polymorphisms in the TRICL4 cohort (34). The risk to develop squamous cell lung 
cancer is significantly reduced in the presence of these polymorphisms (Table 1). We 
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also examined these polymorphisms rs2075803 and rs2258983 in 3795 cases of CRC 
and 3044 controls to estimate the relative risk of developing CRC. Individuals who were 
homozygous A for the rs2075803 SNP and homozygous C for the rs2258983 SNP had 
a significantly reduced risk of developing CRC (Supplemental Table 1). 
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Discussion 
Recent studies have shown that inhibitory CD33rSiglecs can modulate the interactions 
of immune cells with tumor cells by sialic acid-dependent mechanisms (21-23, 25, 26), 
raising the possibility that these Siglecs could be used for a therapeutic checkpoint 
inhibition, analogous to the remarkable recent therapeutics directed against PD-1 or 
CTLA-4 (2). We and others have shown that T cells from healthy humans express low 
levels of CD33-related Siglecs (29, 35). However, we show here that expression of the 
inhibitory Siglec-9 is clearly increased on CD4+ and CD8+ TILs compared with 
peripheral T cells from healthy donors. We also observed the presence of Siglec ligands 
in both cis and trans positions. In addition, we confirmed previous observations that 
have shown a small population of peripheral T cells with Siglec-7 and Siglec-9 
expression (35). Properly glycosylated CD52 has previously been identified as a ligand 
for Siglec-10 on human T cells (36). Furthermore, inhibitory mouse Siglec-G (often 
referred to as the murine paralog of human Siglec-10) was found to inhibit DAMP-
associated T cell activation (37). These investigations demonstrate that Siglecs can 
dampen T cell responses in the context of general inflammation.  
 
How Siglec-9 is upregulated on TILs and how Siglecs are regulated in T cells, including 
intracellular signaling, remains unclear. We observed only a slight upregulation of 
Siglec-9 upon polyclonal and antigen-specific stimulation of healthy T cells. Other 
immune checkpoint receptors are upregulated through repetitive antigenic stimulation or 
the tumor microenvironment including inhibitory cytokines (27). We have seen a similar 
effect in several mice models, indicating that the mechanism for Siglec upregulation in T 
cells appears to be conserved across species, even though Siglec receptors have 
diverged quite a lot between mice and humans. We observed a heterogeneity of the 
frequency in Sig9+ CD8+ T cells in the peripheral blood of healthy donors and an inverse 
correlation with the frequency of naïve CD8+ T cells. This finding suggests that healthy 
individuals with more circulating peripheral memory T cells have also higher number of 
in Sig9+ CD8+ T cells. Until now, mainly Siglec-9 expressing NK cells and myelo-
monocytic cells were associated with immune modulation in cancer. Myeloid cells were 
more reactive in a mouse model of Siglec-E deficiency and an increased 
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immunosurveillance was observed in these mice (21). Engagement of Siglec-9 on 
monocytes/macrophages by a cancer-associated, sialylated glycoform of MUC1 
showed polarization towards immune-suppressive TAMs with upregulation of PD-L1 
(25). Two analyses examined the function of inhibitory Siglec-7 and Siglec-9 in NK cell 
mediated tumor cell killing (22, 23). Other immune receptors including PD-1 are also 
expressed on myeloid cells and NK cells within the tumor (38, 39). Further experiments 
are needed to understand the functional relevance of these immune-modulatory 
receptors including Siglec-9 or PD-1 on cell types other than T cells. However, it is likely 
that CD8+ T cells continue to play central roles in cancer immunotherapy and we define 
Siglec-9 on CD8+ TILs as a new potential therapeutic target for cancer immunotherapy. 
 
Further characterization of Sig9+ CD8+ TILs revealed that these cells co-express several 
inhibitory receptors including PD-1, TIM-3, Lag3 and others. Our analysis suggests that 
Sig9+ CD8+ TILs are a subpopulation of CD8+ PD-1hi TILs, which are often tumor-
specific (40). Co-expression of multiple inhibitory receptors on T cells and also PD-1hi 
TILs were associated with an exhaustion phenotype in cancer including in patients with 
NSCLC (27, 41). Indeed, functional analysis of TILs from NSCLC patients showed a 
significantly reduced capacity to produce cytokines and chemokines (Figure 3). 
However, Sig9+ CD8+ T cells from NSCLC patients were easier to re-activate than Sig9- 
CD8+ T cell despite the increased expression of PD-1 and other inhibitory immune 
receptors on Sig9+ TILs. This finding suggests that Sig9+ CD8+ TILs belong to specific 
subtype within the PD-1hi TILs. A recent analysis of chromatin states in murine and 
human TILs from melanoma and NSCLC patients demonstrated a subpopulation within 
PD-1hi TILs that had a relatively higher expression of CD5 and lower expression of 
CD38 and CD101 and that showed a greater potential for reprogrammability and 
reactivation (31). Our findings showed an enrichment of high CD5 expression and low 
CD38 and CD101 expression on Sig9+ CD8+ TILs in the PD1hi gate. This finding could 
be interpreted as an overlap of Sig9+ CD8+ TILs with this previously described tumor-
specific TIL subpopulation that could be potentially re-activated by immunotherapy. 
Other studies have also shown that not only exhausted TILs co-express a high 
frequency of inhibitory receptors, but also activated TILs (42). This could mean that the 
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Sig9+ CD8+ TILs are in a higher activation state that could potentially be uncovered by 
blocking these different inhibitory receptors (43). 
 
Our analysis also includes functional studies both in vitro with human tissue and in vivo 
in different mouse models to demonstrate the relevance of inhibitory Siglecs on TILs 
and their interactions with cancer-associated Sia-SAMPs. The previous studies have 
provided evidence that Sia-SAMP-Siglec interactions can inhibit immune cell activation 
in in vitro models (21-23, 25). Using bivalent anti-Siglec-9 antibodies (clones 191240 
and E10-286) led to an inhibition of T cell activation and found to be agonistic, which 
might be due to the activation of Siglec-9 signaling by dimerization. In contrast, the use 
of monovalent Fab fragments of the antibody clone 191240 that inhibits Sia-SAMP-
Siglec-9 interactions by hampering ligand binding to the CRD led to increased T cell 
activation. This result suggests that the Sia-SAMP-Siglec-9 interaction can be targeted 
for the enhancement of TIL activation in lung tumors. Functional relevance is further 
supported by the analysis of a Siglec-9 polymorphism in cancer patients. This shows an 
association of hypomorphic alleles with the risk of developing squamous NSCLC. In 
addition, the same alleles were also associated with the risk for colorectal cancer. 
These polymorphisms were previously associated with an increased frequency of 
pulmonary emphysema, exacerbations of chronic obstructive pulmonary disease and a 
hyperactive immune response of myeloid cells (33). While the function of these 
polymorphisms needs to be tested in T cells, their linkage to disease outcome suggest a 
role for Siglec-9 in the development of lung and colorectal cancer. 
 
Our studies also show that the inhibitory Siglec-E receptor – the functional paralog of 
Siglec-9 - on murine T cells – and Sia-SAMPs in the tumor significantly influence the 
immune response to tumors in mouse models. Reduction of Sia-SAMPs by using GNE-
KO tumor cell lines led to significantly reduced growth of tumors. In particular, the use of 
the more antigenic cell line EMT6-HER2 showed rejection of the tumors in some mice 
when hyposialylated GNE-KO tumor cells were used. The knockout of GNE in those cell 
lines could induce additional changes in glycosylation besides reducing the level of 
sialylation. An upregulation of polylactosamine could change the interaction with other 
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immune-modulatory lectins such as galectins (44). Also, during the growth of tumors in 
mice, the cells could acquire sialic acids from the host. Nevertheless, we observed a 
significant growth difference in two different models. Previous experiments with B16 
melanoma cell lines have also shown similar results, although different approaches 
were used for the reduction of tumor sialylation (45). Another analysis with 
hyposialylated methylcholanthrene (MCA)-induced tumors has shown growth inhibition 
of subcutaneous tumors (46). Overexpression of inhibitory Siglec-9 on CD4+ and CD8+ 
T cells led to an increased tumor growth, which indicates a functional role of inhibitory 
Siglecs on T cells. Exchange of inhibitory Siglec-E with activating SigE16 (extracellular 
Siglec-E domain with transcellular activating human Siglec-16) showed a T cell 
dependent growth inhibition. In an adoptive transfer model, we demonstrated that 
Siglec-E on T cells is functionally involved, although the used model with ovalbumin-
specific OT-I T cells has certainly limitations and ovalbumin is not directly comparable to 
naturally occurring tumor antigens. 
 
Cancer immunotherapy and in particular checkpoint blockade with inhibitors of the PD-
1/PD-L1/L2 axis and CTLA-4 are now routinely used in daily oncological practice (1, 
47). However, only a minority of cancer patients shows objective responses under 
checkpoint blockade and only few develop long-term remissions. Thus, combination 
therapies are a promising approach to improve response rates of immunotherapies and 
outcomes for patients (48, 49). Our data suggest that targeting the Sia-SAMP/Siglec-9 
pathway could improve anti-tumor immunity and define this pathway as new inhibitory 
immune checkpoint for T cell activation. 
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Experimental Procedures 
Patients and sample preparation. 
Informed consent was obtained from all patients prior to the sample collection. Surgical 
specimens were mechanically dissociated, digested with accutase (PAA), collagenase 
IV (Worthington), hyaluronidase (Sigma) and DNAse type I (Sigma), filtered, washed 
and frozen for future use. Single-cell suspensions were prepared. Human peripheral 
blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using 
Histopaque-1077 (Sigma) from buffy coats obtained from healthy blood donors (Blood 
Bank, University Hospital Basel, Switzerland). Single-cell suspensions and PBMCs 
were frozen for later use in liquid nitrogen. 
 
Multicolor flow cytometry. 
For multicolor flow cytometry, dead cells were stained using live/dead Fixable Blue dye 
(Invitrogen) and various panels of antibodies. Doublets were excluded in all analyses. 
Corresponding isotype antibodies or fluorescence-minus-one (FMO) samples were 
used as a control, in particular for the Siglec stainings. All tumor samples were analyzed 
with a Fortessa LSR II flow cytometer (BD Biosciences). For infiltration analysis, mice 
were euthanized, and tumors were mechanically dissociated and digested as described 
for the human sample preparation. 
 
Staining for Siglec-7 and Siglec-9 ligands on tumor microarray. 
Tissue microarrays from US Biomax were used for screening of Siglec-9 ligands 
expression in lung cancer samples. For the immunofluorescence staining, recombinant 
human Siglec-hFcs (R&D Systems) were mixed with PE-conjugated anti-human IgG 
(Jackson ImmunoResearch Laboratories) for 1h at 4°C prior to use. For the specific 
visualization of cancer cells, anti-Multi-cytokeratin (Leica Biosystems) staining was 
performed and visualized with a goat anti-mouse IgG coupled to Alexa Fluor 488 (Life 
Technologies). The general fluorescence per sample was measured in a ScanRI 
Microarray Scanner (Perkin Elmer) and processed with ImageJ software version 1.48 
(NIH). Pictures were taken in a fluorescence microscope, original magnification X400 
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(Zeiss). Fluorescence was quantified using ImageJ software and normalized to 
background staining (secondary antibody only). 
In vitro T cell activation and inhibition. 
Murine and human T cells were polyclonally stimulated with anti-CD3 and anti-CD28 
antibodies (BioLegend). Anti-CD3 antibodies (0.5 µg/mL) were either coated overnight 
at 4 °C for human T cells or added soluble for mouse T cells and anti-CD28 added at 1 
µg/mL. For inhibition assays with sialylated LGALS3BP, LGALS3BP was coated 
overnight as well. Activation of T cells was determined by staining for activation and 
proliferation markers by flow cytometry or measuring cytokines in supernatants by 
ELISA. For the Staphylococcal enterotoxin B (SEB) assay, primary NSCLC samples 
were incubated at 200’000 cells/well with SEB (10 ng/mL, Sigma) for 48 hours in the 
presence of full length or digested Fab fragments of the 191240 anti-Siglec-9 antibody 
(R&D Systems). The T cell activation was assessed by FACS staining and IL-2 
secretion measured in the supernatant by ELISA (BioLegend). 
 
RNA sequencing and analysis. 
CD8 positive TILs were sorted from frozen NSCLC samples by FACS according to their 
Siglec-9 expression. Gates used were: lymphocytes, singlets, DAPI- CD3+, CD8+ CD4-. 
RNA was isolated and the library prepared by Microsynth AG (Balgach, Switzerland). 
Next generation sequencing of the library and data analysis was performed by 
Microsynth. Count data from RNAseq samples was analyzed using the edgeR 
Bioconductor package in R. Filtered genes, expressed at >1 count per million (cpm) in 
at least three samples were analyzed using the QLF functions with batch correction for 
patients. All genes were ranked according to their F statistics comparing Siglec-9 
positive and negative samples. A weighted gene set enrichment analysis (GSEA) was 
performed using this pre-ranked list using the GSEA java application 
(http://www.broad.mit.edu/gsea/). Boxplots comparing expression levels between 
Siglec9 positive and negative cells was performed in R using logarithmically 
transformed cpm values. The dataset has been uploaded to Gene Expression Omnibus 
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(GEO, https://www.ncbi.nlm.nih.gov/geo, access number GSE115305). 
 
GNE-deficient cells and in vitro tumor cell killing with CD3/EpCAM TCB or CD3/CD19 
TCB. 
Human and murine GNE-deficient tumor cell lines were created using CRISPR/CAS9. 
Guide RNAs were designed online using ‘e-crisp.org’, synthesized by Microsynth AG 
(Balgach, Switzerland) and cloned into the pX458 vector (Addgene). A549, HT-29 and 
RAMOS cell lines were bought from ATCC. After transient transfection in tumor cells, 
single cell sorting and subsequent screening for cell surface sialylation was performed. 
Multiple GNE-deficient clones were pooled in order to avoid clonal selection when 
comparing to WT cell lines.  
GNE-deficient cell lines and cell lines refed with 5 mM Neu5Ac for 24h. Co-incubation 
with magnetically isolated CD8 T cells from healthy donors or tumor samples in the 
presence of catumaxomab (anti-CD3/anti-EpCAM, Fresnius) or blinatumomab, (anti-
CD3/anti-CD19, Amgen) were performed at a concentration of 10 ng/ml. Alternatively, 
the respective cell lines were stained with CSFE (Sigma-Aldrich) and spiked into full 
tumor digests obtained from primary NSCLC or CRC samples. Tumor cell killing was 
analyzed by FACS staining for cleaved caspase 3 and by live dead staining. Tumor 
cells were gated by size and expression of EpCAM or CD19 respectively, as well as by 
negative gating using CD3, CD8 and CD4.  
 
Genetic mouse models for in vivo analysis of Siglec function on T cells.  
Siglec-9 transgenic mice were described previously (21). Siglec-9 transgenic mice 
(B6.Cg-Tg(CAG-Siglec9)1Avrk) were crossed with CD4-Cre mice (B6Tg(CD4-cre)1Cwi) 
to obtain a T cell specific overexpression of inhibitory human Siglec-9 in the C57Bl6 
background. Transgenic mice expressing SigE16 chimeric Siglec-E with 
transmembrane and intracellular domain of activating human Siglec-16 (B6.Cg-
Siglece<tm4E16Avrk>) were also described previously (18). Tumor cell lines were 
injected into 8 to 12-week old female mice, and tumor growth monitored as described 
above. 
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SigE16 were crossed into OT-I transgenic mice. For the adoptive transfer of ovalbumin-
specific OT-I cells from WT or SigE16 mice, T cells were harvested from splenocytes 
and injected into WT C57Bl6 mice bearing subcutaneous MC38-OVA tumors. T cells 
were followed for proliferation by labeling with Cell Trace Violet (CTV). Tumor growth 
was measured, and cell numbers determined by counting beads and flow cytometry. 
 
Association study of Siglec-9 polymorphism 
The association analysis of Siglec-9 polymorphisms in lung cancer was studied on the 
TRILC cohort (34). In total, 11348 patients with lung cancer and 15861 controls were 
studied for the rs2075803 and the rs2258983 SNP. An association test was performed 
after adjusting for age, gender, and top significant principal components. Then, we 
conducted a fixed effects meta-analysis with an inverse variance-weighted average 
method to combine the summary data from each association test. Meta-analysis was 
performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). For the analysis 
of an association of Siglec-9 polymorphisms with the risk of colorectal cancer, SNP 
genotypes for rs2075803, rs2258983 among cases and controls from imputed genotype 
data derived from samples genotyped on the Oncoarray platform and USC Norris 
Cancer Center were used (informed consent was obtained from all patients). Using 
contingency table analysis (Fisher’s test), we calculated odds ratios, 95% confidence 
intervals and p-values using an additive model, and genotype-specific odds ratios. 
 
Statistical analysis 
Statistical significance between two groups was determined using two tailed Student’s t 
tests. Significance between more than two conditions was assessed using one-way 
ANOVAs with multiple comparisons. For survival curve analysis, two-way ANOVA was 
used. Survival analysis was performed by the Gehan-Breslow-Wilcoxon test and 
multivariate analysis was done by Cox proportional hazard analysis. A P value <0.05 
was considered statistically significant. 
 
Study approval 
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The local ethical committee in Basel, Switzerland approved the sample collection and 
the use of clinical data (Ethikkomission Nordwest- und Zentralschweiz, EK321/10 and 
UBE 15–106). Mouse experiments were approved by the local committee of Basel Stadt 
(approval number 2747). 
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Figure Legends 
 
Figure 1 Siglec-9 is upregulated on CD8+ TILs. 
(A) Representative flow cytometry analysis of Siglec-9 expression on CD8+ T cells in 
PBMCs from healthy donors (left panel), PBMCs from NSCLC patients (middle panel) 
and TILs from a matched NSCLC patient (right panel). (B, C), Quantification of Siglec-9 
expression on CD4+ (B) and CD8+ (C) TILs from NSCLC patients (PBMCs n=36, 
NSCLC n=41, mean±s.d.). Statistical analysis by unpaired Student’s t test. (D) Paired 
analysis of CD8+ T cells from the peripheral blood and tumors of NSCLC patients 
(n=20). Statistical analysis by paired Student’s t test. (E) Immunohistochemical staining 
of Siglec-9 positive cells in NSCLC sections. Scale bars represent 50 μm. (F) 
Representative immunofluorescence analysis of CD3 and Siglec-9 double positive cells 
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(left panel; arrow shows double positive cell; scale bar=30 μm) and Siglec-9 staining or 
SNA staining and Siglec-9 staining (right panel, scale bar=50 μm). (G) Heatmap of 
expression analysis of different Siglecs in NSCLC samples on CD4+ and CD8+ TILs. 
and (H, I) Immunofluorescence study in paraffin-embedded tissue microarrays using 
recombinant Siglec-9-Fc (human IgG1) fusion protein coupled to secondary PE-
conjugated (Fab′)2 goat anti-human Fc antibody. Representative images (H) and Siglec 
ligands quantification summary (I) are shown. The pictures were taken with an original 
magnification x400, the scale bars represent 50μm. Fluorescence values were 
normalized against an IgG1 isotype control (lung tissue n=5, adjacent lung tissue n=9, 
squamous cell carcinoma SCC n=20, adenocarcinoma n=20, small cell lung cancer 
SCLC n=10, broncho-alveolar carcinoma BAC n=10, atypical carcinoid n=5, mean 
±s.e.m.). Statistical analysis was performed by 1-way-ANOVA. *P<0.05, **P<0.01, 
***P<0.001.  
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Figure 2 Sig9+ CD8+ TILs co-express inhibitory receptors.  
(A, B) Expression of PD-1 in primary NSCLC samples on Sig9- CD8+ or Sig9+ CD8+ 
TILs (A, n=44) and representative FACS analysis (B). Statistical analysis by paired 
Student’s t test. (C, D) Expression of TIM-3 (C, n=71) and LAG-3 (D, n=18) on Sig9- 
CD8+ or Sig9+ CD8+ TILs from NSCLC samples. Statistical analysis by paired Student’s 
t test. (E) Analysis of the number of co-expressed inhibitory receptors on Sig9- CD8+ or 
Sig9+ CD8+ TILs. (F) Volcano plot of RNA sequencing on sorted TILs according to their 
Siglec-9 expression. The three significantly differentially expressed genes were MIK67 
(Ki67), KLF4 and SPP1. *P<0.05, ***P<0.001. Data presented as mean±s.d. 
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Figure 3 Sig9+ CD8+ TILs are a distinct subset within intratumoral CD8+ T 
cells. 
(A, B) Upregulation of the activation marker CD25 (A) and CD69 (B) on Sig9- CD8+ or 
Sig9+ TILs sorted from primary NSCLC samples and activated with anti-CD3/28 
antibodies for 48h (n=9). Statistical analysis by paired Student’s t test. (C) ELISA 
analysis of IFNg in the supernatant of sorted Sig9- CD8+ T cells or Sig9+ CD8+ T cells 
(n=3-7, independent patients). Cells were sorted from PBMCs of healthy donors (HD) or 
primary NSCLC samples (TILs). Supernatants from 50’000 cells were analyzed. (D) 
Analysis of TNFa in the supernatant of sorted Sig9- CD8+ or Sig9+ CD8+ cells from 
healthy donors or NSCLC patient samples (n=3-7, independent donors/patients). 
Statistical analysis was performed by 1-way-ANOVA. (E) Expression level of CD5 in the 
CD8+ PD1hi population on Sig9- TILs and Sig9+ TILs (n=9). (F) Percent of Sig9- CD8+ 
TILs or Sig9+ CD8+ TILs in primary NSCLC samples that express Ki67 within the PD1hi 
population (n=9). (G) Frequency of CD38hi CD101hi cells on Sig9- and Sig9+ CD8+ PD1hi 
TILs determined by flow cytometric analysis (n=13). Statistical analysis by paired 
Student’s t test. *P<0.05, **P<0.01, ***P<0.001. Data presented as mean±s.d. 
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Figure 4 Sialoglycan-SAMPs inhibit T cell-mediated tumor cell killing in vitro.  
(A) Inhibition of T cell activation by LGALS3BP in a dose-dependent manner measured 
by intracellular IFNg by flow cytometry. CD8+ T cells from healthy donors were activated 
with anti-CD3 and anti-CD28 antibodies in presence of increasing amounts of 
LGALS3BP (µg/mL, n=3). (B) Representative histograms of binding of Sig9-Fc to A549 
WT cells, enzymatically desialylated A549 cells (desia), GNE-deficient A549 cells (GNE-
KO) and GNE-KO A549 cells refed with 10 mM Neu5Ac. (C) Percentage of cleaved 
caspase 3 positive (clCasp3+) WT A549 cells, desialylated A549 cells, GNE-KO A549 
cells or GNE-KO A549 cells fed with Neu5Ac (refed) after incubation with CD8+ T cells 
and catumaxomab (n=10). (D) Apoptosis of WT, desialylated, GNE-KO and refed GNE-
KO HT-29 cells measured by upregulation of cleaved caspase 3 in tumor cells (n=6). (E, 
F) clCaps3+ A549 (E, n=11) or HT-29 (F, n=11) tumor cells after co-incubation with TILs 
from NSCLC or CRC samples. (G) CD8+ T cells were sorted according to their Siglec-9 
expression and incubated with either WT or GNE-KO A549 cells (n=4). (H) CD19+ 
RAMOS cells were incubated with CD8+ T cells from healthy donors in the presence of 
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CD3 and CD19 bispecific antibody blinatumomab (n=7). (I) GNE-KO RAMOS cells 
incubated with CD8+ T cells from patients with chronic lymphocytic leukemia (n=3). (J) 
Activation measured by CD25 on CD8+ T cells treated with anti-CD3 and anti-CD28 
antibodies in presence of anti-Siglec-9 antibody (clone 191240, µg/mL, n=4). (K) 
Relative IL-2 production of NSCLC primary tumor samples incubated with SEB and 
Siglec-9 blocking antibody and the Fab fragments (clone 191240, n=5). (L) 
Measurement of CD69 upregulation on CD8+ TILs from NSCLC patients upon 
incubation with SEB in presence of antibodies or Fab fragments (n=5). Statistical 
analyses in this figure were performed by 1-way-ANOVA. Data presented as mean±s.d. 
*P<0.05, **P<0.01, ***P<0.001. 
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Figure 5 Sialylated-SAMPs enhance immune escape and tumor growth in 
vivo. 
(A) Siglec-E expression was determined by flow cytometry on control (ctrl) splenocytes, 
splenocytes from tumor-bearing mice and CD8+ TILs from subcutaneous MC38 tumors 
(n=25-28). Statistical analysis was performed by 1-way-ANOVA. (B) Expression of 
intracellular Ki67, was examined by flow cytometry on SigE- CD8+ and SigE+ CD8+ TILs 
(n=18). Statistical analysis by paired Student’s t test. (C-E) Frequencies of inhibitory 
immune receptor expression on SigE- CD8+ and SigE+ CD8+ TILs from MC38 tumors as 
studied by flow cytometry PD-1 (C, n=16), TIM-3 (D, n=18), and LAG-3 (E, n=7) were 
analyzed. Statistical analysis by paired Student’s t test. (F) Number of co-expressed 
inhibitory receptors on SigE- CD8+ or SigE+ CD8+ TILs. (G) Upregulation of CD25+ 
CD69+ upon re-stimulation of sorted SigE- CD8+ and SigE+ CD8+ TILs. Statistical 
analysis by paired Student’s t test. (H) Growth curves of subcutaneous WT or GNE-
deficient (GNE-KO) MC38 tumors (n=8-9). (I) Growth curves of subcutaneous WT and 
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GNE-KO EMT6 tumors (n=13-14). Experiments were replicated 2-3 times. Statistical 
analysis by 2-way-ANOVA. (J, K) Frequencies of CD3+ and CD8+ cells in the tumor 
(n=7). Statistical analysis by unpaired Student’s t test. **P<0.01, ***P<0.001. Data 
presented as mean±s.d. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPs mediate cancer immune evasion	
Stanczak et al. 35 
 
Figure 6 Engagement of inhibitory Siglecs on T cells mediates immune 
escape. 
(A) Subcutaneous growth curves of MC38 tumors in littermate Siglec-9 transgenic 
control mice (HS9) or Siglec-9 transgenic mice crossed to CD4-Cre mice (HS9, 
CD4Cre) (n=8-10). The experiment was repeated 3 times. Statistical analysis by 2-way-
ANOVA. (B) Tumor volumes after 21 days of subcutaneous MC38 tumors in littermate 
control mice (E/E), or homozygous (E16/E16) mice that express the chimeric receptor 
SigE16 (n=7). Statistical analysis was performed by 1-way-ANOVA. (C) Subcutaneous 
growth curves of MC38 tumors in E16 mice or littermate control mice after CD4 and 
CD8 cell depletion by antibodies (n=7-8). The experiment was repeated 2 times. 
Statistical analysis by 2-way-ANOVA. (D) MC38 tumor volumes after 21 days in E16 
mice and littermate control mice and independent depletion of CD4 and CD8 T cells.  
(E) Tumor volume of MC38-OVA tumors after adoptive transfer of ovalbumin-specific 
OT-I CD8+ T cells from WT or SigE16 (E16) mice. Statistical analysis was performed by 
1-way-ANOVA. *P<0.05, **P<0.01. Data presented as mean±s.d. (F) Survival analysis 
of NSCLC patients with low (n=18) and high percentage (above 30%, n=11) of Siglec-9 
expression on their CD8+ T cells. Differences were analyzed by the Wilcoxon test. A 
multivariate analysis of the two groups for age and stage show a slightly reduced 
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significance with a P value of 0.0669 (multivariate, univariate analysis P=0.0097) and a 
hazard ratio of 14.6. 
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Table 1 Risk for lung cancer depending on Siglec-9 polymorphisms 
 
OR, odds ratio; 95%CI_l, 95% lower confidence interval; 95%CI_u, 95% upper confidence 
interval; P value by Cox proportional regression analysis, multivariate analysis for age, gender 
and top significant principal components form previous studies. 		
 
 
rs_number reference 
allele 
effect 
allele 
OR 95%CI_l 95%CI_u P value 
NSCLC 
 
rs2075803 A G 0.998 0.963 1.035 0.92 
NSCLC 
 
rs2258983 C A 0.998 0.962 1.035 0.91 
Adenocarcinoma 
 
rs2075803 A G 1.03 0.974 1.09 0.29 
Adenocarcinoma 
 
rs2258983 C A 1.036 0.978 1.097 0.23 
Squamous 
 
rs2075803 A G 0.939 0.888 0.993 0.027 
Squamous 
 
rs2258983 C A 0.936 0.884 0.991 0.023 
